The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2020.09.24.20200857: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Although a conventional cost-effectiveness framework has its limitations during a pandemic, we find that even from the more conservative healthcare perspective the net benefits of vaccination are positive. Arguably, the monetary value per QALY could be different in this pandemic to the normal decision rules used in the UK given that (i) …
SciScore for 10.1101/2020.09.24.20200857: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Although a conventional cost-effectiveness framework has its limitations during a pandemic, we find that even from the more conservative healthcare perspective the net benefits of vaccination are positive. Arguably, the monetary value per QALY could be different in this pandemic to the normal decision rules used in the UK given that (i) the value of the opportunity costs of COVID-19 admissions may be lower,22 (ii) we quantified the reduction in health loss and people generally prefer to avoid losses (loss aversion),23 and (iii) the health opportunity costs will change with COVID-19 given that the overall health sector budget may shift and COVID-19 will have an impact on the efficiency of other healthcare interventions. Some have also argued that a higher discount rate may be justified given that past policy decisions before the emergence of SARS-CoV-2 imply a relatively low value was placed on future non-influenza pandemics.24 We also highlight the potential magnitude of broader societal benefit, but given that our methods are simple, and the need for further macroeconomic modelling, we did not explore other future research avenues such as threshold pricing against a cost-effectiveness threshold or net societal benefit. Strengths and Limitations: We extended an age-structured dynamic-transmission model that was previously used to inform UK policies on introducing non-pharmaceutical interventions to provide early insights into the health and economic value of SARS-CoV-2 vaccin...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
-
